Publikationen in Zusammenarbeit mit Forschern von Hospital Universitario de Salamanca (22)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2020

  1. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

    Cancers, Vol. 12, Núm. 6

2019

  1. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis

    Hepatology, Vol. 70, Núm. 2, pp. 547-562

2013

  1. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

2008

  1. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer

    Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814

1993

  1. Metabolism of ketamine in rat gut and brain microsomial fractions.

    European Congress of Biopharmaceutics and Pharmacokinetics (5º. Bruselas. 1993) : Participants' papers

1992

  1. Cimetidine versus ranitidine : the effect on the pharmacokinetics of theophylline ininsolated perfused rat liver

    Symposium of the International Society for the study of xenobiotics (Bolonia. 1992) : proceedings

  2. Efecto de dosis equimoleculares de cimetidina y ranitidina sobre la eliminación deteofilina

    Reunión Científica de la Asociación de Docentes de Farmacia Galénica (1º. Madrid. 1992)

1991

  1. Biotransformation kinetics of binifibrate and identification of its metabolites

    Bolletino Chimico Farmaceutico, Vol. 130, pp. 172-177

  2. Influence of excipient in the release of ketamine from suppositories

    Bolletino Chimico Farmaceutico, Vol. 130, pp. 52-54

  3. Pharmacokinetics of dibenzylamine administered as a drug delivery system withcefazoline

    Biopharmaceutics and Drug Disposition, Vol. 11, pp. 259-264

1989

  1. Determination of low concentrations of dibenzylamine in human plasma and urine bygas chromatography with a nitrogen phosphorus detector

    Journal of Chromatography. Biomedical Applications, Vol. 490, pp. 206-212

1988

  1. Choice of optimum pharmacokinetic model of orally administered paracetamol

    Biopharmaceutics and Drug Disposition, Vol. 9, pp. 389-396

1987

  1. Contribución del Servicio de Farmacia en un programa de tratamiento deheroinómanos.

    Congreso Nacional de la Asociación Nacional de Farmacéuticos de Hospitales. (32. Salamanca. 1987)

  2. Estudio de bioequivalencia de dos formulaciones orales de paracetamol

    Farmacia Hospitalaria XXXII. Tomo I (Madrid : Asociación Española de Farmacéuticos de Hospitales, 1987), pp. 117-123

  3. Monitoring of serum levels of amitriptyline in overdose.

    Proceedings del III Congreso Europeo de Biofarmacia y Farmacocinética

  4. Pharmacokinetics and Clinical evaluation of ketamine administered by the IV andepidural routes

    International Journal of Clinical Pharmacology,Therapy and Toxicology, Vol. 25, pp. 77-80

1986

  1. Bioavailability of amoxapine in experimental animals

    Bolletino Chimico Farmaceutico, Vol. 135, pp. 307-311

  2. Urinary and Biliary excretion kinetics of ketamine and its metabolites in the rabbit

    Bolletino Chimico Farmaceutico, Vol. 125, pp. 357-361